Navigation Links
Study indicates nanoparticles could help pain-relieving osteoarthritis drugs last longer
Date:10/26/2011

Arlington, Va. A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research is being presented Oct. 23 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."


'/>"/>

Contact: Stacey May
MayS@aaps.org
703-248-4740
American Association of Pharmaceutical Scientists
Source:Eurekalert

Related medicine news :

1. Study shows why underrepresented men should be included in binge eating research
2. Some Asthma Drugs Raise Risk of Complications, Especially in Kids: Study
3. Sleepy Teens More Prone to Weight Gain: Study
4. Scott & White Healthcare and American Cancer Society enter into partnership for prevention study
5. IADR/AADR publish study on dental caries vaccine
6. Penn study explains paradox of insulin resistance genetics
7. Wayne State University study of heroin users to examine links between stress, drug use
8. Study Casts Doubt on Hot Dogs Link to Colon Cancer
9. Study: Obesity limits effectiveness of flu vaccines
10. Soft Drinks Linked to Violent Tendencies in Teens: Study
11. Yoga, Stretching Classes Outdo Self-Care for Back Pain: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... An inventor ... amputees to safely ride all types of amusement park rides. , The patent-pending SAFETY ... unit is easy to use and could be set up in a matter of ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Cable Network (PCN) during the summer of 2016. The program was made possible ... the United States Department of Health and Human Services Administration. The broadcast, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a ... and Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative ... of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, cancer ... announced the center's president and CEO, Dr. Daniel Messina. , Among the recognitions, ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Research and Markets has announced the addition of the "Endodontic ... ... analyzes the worldwide markets for Endodontic Supplies in US$ Thousand. The report provides ... Japan , Europe , Asia-Pacific , ... estimates and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:12/8/2016)... Mederi Therapeutics Inc . anunciou aprovação regulatória, pela CFDA, e lançamento de ... refluxo gastroesofágico (DRGE). Foto -  http://photos.prnewswire.com/prnh/20161207/446903 ... ... procedure performed and broadcast during the Chinese Congress of Digestive Endoscopy, by Professor ... , , ...
(Date:12/8/2016)... , Dec. 8, 2016 Bodycad announced ... for improving the accuracy, reproducibility and speed for ... long and small bone orthopaedic applications. These patents ... creating personalized orthopaedic restorations based on each patient,s ... restorations, the company harnesses the world,s first suite ...
Breaking Medicine Technology: